IBM has released an enterprise version of its WebSphere Web application server software for businesses with large transaction-rate needs.
WebSphere Enterprise Edition uses Enterprise Java-Beans to connect legacy data to a high-performance transaction-based Web site at the front end.
It will be available from September in the US but will not be offered in the UK until next year, with British pricing not yet set. It will cost $35,000 (£22,300) in the US, with an additional tool kit to cost $7,500 (£4,800) per developer.
The software builds on the existing standard and advanced versions of Websphere, launched last year, and combines IBM's TXSeries and Component Broker technology with Enterprise Java-Beans.
Nigel Beck, director of WebSphere marketing, said IBM will no longer sell TXSeries and Component Broker separately.
Websphere Enterprise Edition will run on OS/390, NT, AIX and Solaris, but not on NetWare. Although WebSphere standard edition comes with NetWare as standard, Paraic Sweeney, WebSphere's marketing vice president, said NetWare was "not suited to large-transaction systems".
The new edition does have some overlap with existing IBM products, however.
Asked whether the WebSphere Enterprise Edition would make Lotus Domino, which also provides a platform for Web applications, effectively redundant, Sweeney said: "It's like having a sports car and a bus. A sports car would be better for a country drive, but if you're transporting a football team to a match, the bus is better."
Scientists create a virtual reality simulation of a black hole sitting at the centre of the Milky Way
Simulations like this can help people understand complicated systems in the universe in a better way
The most luminous galaxy ever discovered is cannibalising at least three of its smaller neighbours, study finds
The galaxy radiates at 350 trillion times the luminosity of the Sun
Researchers modify genetic code of cancer-killing virus so it can target cells that protect cancer from immune system
Changing the genetic coding causes the infected cancer cells to produce a protein that kills the fibroblast cells that protect cancer
The findings can help improve the current understanding of brain development disorders, such as epilepsy or autism